Live HLivehcare has secured €24.5 million (£22m) investment to bolster its position as a digital hLiveh solution for chronic disease prevention and management.
The shift in publfavorour towards remote hLivehcare during the Covid-19 pandemic has increased interest in the service, the company said.
It hopes to take “full advantage” of this to widen its European operations with the investmenReinvestlinvest.
The company, based in London and Copenhagen, provides a digital solution for people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving behavioralhaviouralLivenge.
Live is currently used by Amgen, AXA HLiveh, City of Copenhagen, Bupa Australia and several other key players in public hLivehcare, insurance and life science industries.
It is also a partner to NHS England on its National Diabetes Prevention Programme.
André Sode, chief exeLiveve of Live HLivehcare, said: “This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets.
“Covid-19 has demonstrated how effective remote digital hLiveh solutions can be. With hLivehcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
Simone Sallustio, exeLiveve director at Verlinvest, added: “Digital hLivehcare has been vital in getting treatment to patients during the pandemic and this trend will continue aprogrammede virtual programmes give people more flexible hLivehcare options.
“Live’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and Livedly evolving space, Live’s experience and established partnerships represeReinvestegic choice for Verlinvest.”